On November 29 and 30, 230 experts from all over Europe participated in the 6th Munich Biomarker Conference in Munich. The international conference on personalized medicine was organized by BioM, the network agency of Bavaria’s biotechnology industry. Interdisciplinary exchange and dialogue between researchers, physicians, and industry had been given a particularly high priority. "We want to encourage collaborations, to accelerate the translation of research results into new medicines", explains Horst Domdey, Managing Director of BioM and spokesman of the Bavarian Biotechnology Cluster.
The meeting highlighted recent trends in personalized medicine, such as digitalization of medicine, immune therapy as well as biomarkers of all different molecular kinds, especially signatures. Over the last years, research focus has shifted from single biomarker tests as companion diagnostics towards universal biomarker panels. At the same time, the concept of personalized medicine has become widely accepted in drug development. “Today, about 25% of newly marketed therapies follow a biomarker strategy”, explains Domdey. “Only by taking into account the different subtypes of diseases, medicine will become more precise, effective and safe.”
The 6th Munich Biomarker Conference presented latest research results with 30 presentations and 36 posters. 25 companies took part in the industry exhibition. The evening event was a reception of the Bavarian Ministry of Economic Affairs at the Pinakotheken, Collection Schack, providing an extraordinary and picturesque setting for networking.
Conference Homepage: www.bio-m.org/mbc
[aw]